The optimal use of bexarotene in cutaneous T-cell lymphoma.

Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol (2015) 0.89

Primary cutaneous lymphomas: diagnosis and treatment. Postepy Dermatol Alergol (2015) 0.84

Combination of bexarotene and the retinoid CD1530 reduces murine oral-cavity carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide. Proc Natl Acad Sci U S A (2014) 0.83

Adaptors for disorders of the brain? The cancer signaling proteins NEDD9, CASS4, and PTK2B in Alzheimer's disease. Oncoscience (2014) 0.82

Drug metabolism and clearance system in tumor cells of patients with multiple myeloma. Oncotarget (2015) 0.80

Design, synthesis, and biological evaluation of indenoisoquinoline rexinoids with chemopreventive potential. J Med Chem (2013) 0.79

The emerging role of bexarotene in the treatment of Alzheimer's disease: current evidence. Neuropsychiatr Dis Treat (2015) 0.79

Identification, synthesis, and biological evaluation of the metabolites of 3-amino-6-(3'-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11-(6H)dione (AM6-36), a promising rexinoid lead compound for the development of cancer chemotherapeutic and chemopreventive agents. J Med Chem (2012) 0.79

Bexarotene gel: a new topical therapy for alopecia areata. Int J Trichology (2010) 0.78

Identification of Bexarotene as a PPARγ Antagonist with HDX. PPAR Res (2015) 0.78

Retinoid X Receptor-selective Signaling in the Regulation of Akt/Protein Kinase B Isoform-specific Expression. J Biol Chem (2015) 0.76

Effect of a retinoid X receptor partial agonist on airway inflammation and hyperresponsiveness in a murine model of asthma. Respir Res (2017) 0.75

Discovery of a Potent Retinoid X Receptor Antagonist Structurally Closely Related to RXR Agonist NEt-3IB. ACS Med Chem Lett (2011) 0.75

Polyunsaturated fatty acid deficiency during neurodevelopment in mice models the prodromal state of schizophrenia through epigenetic changes in nuclear receptor genes. Transl Psychiatry (2017) 0.75

Suppressive effects of RXR agonist PA024 on adrenal CYP11B2 expression, aldosterone secretion and blood pressure. PLoS One (2017) 0.75

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48

Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med (1999) 6.04

Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg (1996) 5.05

Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell (1999) 5.01

What is subjective global assessment of nutritional status? JPEN J Parenter Enteral Nutr (1987) 4.21

T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature (1985) 3.71

Long latency precedes overt seroconversion in sexually transmitted human-immunodeficiency-virus infection. Lancet (1987) 3.68

Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma. N Engl J Med (1999) 3.37

Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med (1987) 3.13

Use of monospecific antisera and cRNA probes to localize the major changes in keratin expression during normal and abnormal epidermal differentiation. J Cell Biol (1988) 2.88

EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood (1997) 2.85

Binding of triple helix forming oligonucleotides to sites in gene promoters. Biochemistry (1991) 2.73

Ineffectiveness of AIDS education and HIV antibody testing in reducing high-risk behaviors among injection drug users. Am J Public Health (1992) 2.43

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol (2001) 2.24

BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel. Br J Dermatol (2013) 2.17

Extracorporeal photopheresis in Sézary syndrome. No significant effect in the survival of 44 patients with a peripheral blood T-cell clone. Arch Dermatol (1998) 2.04

Fractionation, morphological and functional characterization of effector cells responsible for human natural killer activity against cell-line targets. Cell Immunol (1979) 1.94

Identification of resting human T and B lymphocytes by acid alpha-naphthyl acetate esterase staining combined with rosette formation with Staphylococcus aureus strain Cowan 1. Scand J Immunol (1976) 1.91

Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. Blood (1997) 1.89

Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol (2001) 1.88

Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol (1998) 1.79

Reinforcement contingencies and signal detection. J Exp Anal Behav (1982) 1.77

Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol (1992) 1.75

Localized scleroderma in breast cancer patients treated with supervoltage external beam radiation: radiation port scleroderma. J Am Acad Dermatol (1996) 1.75

Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells. Blood (2001) 1.74

Hepatitis C virus in dermatology. A review. Arch Dermatol (1995) 1.71

Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells. Proc Natl Acad Sci U S A (1987) 1.70

Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. J Immunol (1991) 1.68

T-cell and T/natural killer-cell lymphomas involving ocular and ocular adnexal tissues: a clinicopathologic, immunohistochemical, and molecular study of seven cases. Ophthalmology (1999) 1.66

Primary cutaneous pleomorphic small T-cell lymphoma. A review of 11 cases. The French Study Group on Cutaneous Lymphomas. Arch Dermatol (1995) 1.64

Cytokine loops involving interferon-gamma and IP-10, a cytokine chemotactic for CD4+ lymphocytes: an explanation for the epidermotropism of cutaneous T-cell lymphoma? Blood (1995) 1.62

Diagnostic value of dominant T-cell clones in peripheral blood in 363 patients presenting consecutively with a clinical suspicion of cutaneous lymphoma. Blood (2000) 1.59

A subcutaneous delta-positive T-cell lymphoma that produces interferon gamma. N Engl J Med (1991) 1.59

Morphological and functional characterization of isolated effector cells responsible for human natural killer activity to fetal fibroblasts and to cultured cell line targets. Immunol Rev (1979) 1.58

Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. Blood (1996) 1.52

Approach to the study of the role of sex hormones in autoimmunity. Arthritis Rheum (1979) 1.51

Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin. Eur J Cancer (2002) 1.51

Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer (1997) 1.50

Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin. J Invest Dermatol (1997) 1.50

Autoimmune regulator is expressed in the cells regulating immune tolerance in thymus medulla. Biochem Biophys Res Commun (1999) 1.48

Indolent cutaneous prodrome of fatal HTLV-I infection. Lancet (1990) 1.48

Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol (2007) 1.47

Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056). Br J Dermatol (2012) 1.46

Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol (1998) 1.46

Cholesterol, essential fatty acids, and suicide. Pharmacopsychiatry (2002) 1.46

Basal cell carcinomas in a tertiary referral centre: a systematic analysis. Br J Dermatol (2014) 1.46

Idiopathic CD4+ T lymphocytopenia in a patient with mycosis fungoides. J Am Acad Dermatol (1994) 1.45

Extracorporeal photopheresis in Sézary syndrome. Lancet (1997) 1.44

Cyclosporin A inhibits the antigen-presenting functions of freshly isolated human Langerhans cells in vitro. J Invest Dermatol (1991) 1.44

Hemorrheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks. Metabolism (2001) 1.42

PAX3 is expressed in human melanomas and contributes to tumor cell survival. Cancer Res (2001) 1.42

Significance of restricted HIV expression for HIV neuropathogenesis: still an unresolved issue. AIDS (1997) 1.41

Zidovudine for the treatment of HIV-negative patients with psoriasis: a pilot study. J Am Acad Dermatol (1995) 1.40

In melanoma, beta-catenin is a suppressor of invasion. Oncogene (2011) 1.40

Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene. Proc Natl Acad Sci U S A (1998) 1.40

The South African Pilot Hospital Accreditation Programme. Part II. The development of standards. S Afr Med J (1994) 1.39

[Medical activity in a emergency outpatient department dermatology]. Ann Dermatol Venereol (2003) 1.38

Specific cellular immune response and neutralizing antibodies in goats immunized with native or recombinant envelope proteins derived from human T-lymphotropic virus type IIIB and in human immunodeficiency virus-infected men. Proc Natl Acad Sci U S A (1987) 1.37

[Mystery of the blue man: alkaptonuria]. Duodecim (1997) 1.37

The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther (1998) 1.36

The South African Pilot Hospital Accreditation Programme. Part I. The process. S Afr Med J (1994) 1.36

Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol (2001) 1.35

Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood (1996) 1.34

Benefit from hypocaloric diet in obese men depends on the extent of weight-loss regarding cholesterol, and on a simultaneous change in body fat distribution regarding insulin sensitivity and glucose tolerance. Metabolism (1992) 1.33

Patient safety in developing countries: retrospective estimation of scale and nature of harm to patients in hospital. BMJ (2012) 1.33

Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol (2009) 1.32

European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol (2006) 1.30

Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol (2001) 1.28

Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities. Arch Dermatol (1996) 1.28

Alopecia areata and cytomegalovirus infection in twins: genes versus environment? J Am Acad Dermatol (1998) 1.27

Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol (2013) 1.27

Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas. Blood (2000) 1.27

Pineal and CNS germ cell tumors: Royal Marsden Hospital experience 1962-1987. Int J Radiat Oncol Biol Phys (1990) 1.25

Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood (1998) 1.24

Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci U S A (2001) 1.24

Tissue and cellular distribution of an adhesion molecule in the carcinoembryonic antigen family that serves as a receptor for mouse hepatitis virus. Lab Invest (1995) 1.21

Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. Leukemia (2007) 1.21

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol (1997) 1.20

Severe neonatal Marfan syndrome resulting from a de novo 3-bp insertion into the fibrillin gene on chromosome 15. Am J Hum Genet (1994) 1.20

Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin disease. Blood (2000) 1.20

Cardiac resuscitation with percutaneous cardiopulmonary support. Lancet (1992) 1.19

Clonal T-cell receptor gamma-chain gene rearrangement by PCR-based GeneScan analysis in advanced cutaneous T-cell lymphoma: a critical evaluation. J Pathol (1999) 1.18

Immunohistochemical and electron microscopic characterization of the cellular infiltrate in alopecia (areata, totalis, and universalis). J Invest Dermatol (1984) 1.17

Biomarkers in melanoma. Ann Oncol (2009) 1.17

Characterization of the immunocompetent cells of rheumatoid synovium from tissue sections and eluates. Arthritis Rheum (1981) 1.17

First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol (2011) 1.16

When the bough breaks: provider-initiated comprehensive care is more effective and less expensive for sole-support parents on social assistance. Soc Sci Med (2001) 1.16

Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology (1994) 1.16

High rates of disseminated infection due to non-tuberculous mycobacteria among AIDS patients in Finland. J Infect (1999) 1.15

Multiplex PCR for rapid detection of T-cell receptor-gamma chain gene rearrangements in patients with lymphoproliferative diseases. Br J Haematol (1996) 1.15

AIDS exacerbates psoriasis. N Engl J Med (1985) 1.15

Human natural cell-mediated cytotoxicity against fetal fibroblasts. III. Morphological and functional characterization of the effector cells. Cell Immunol (1979) 1.15

Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia (2011) 1.15

Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. J Eur Acad Dermatol Venereol (2010) 1.13

Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med (1999) 1.13

What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol (2010) 1.13

Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol (2000) 1.12

Needle-use practices among intravenous drug users in an area where needle purchase is legal. AIDS (1991) 1.12